Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine

▴ Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age or older received V114 or PCV13 followed by PNEUMOVAX 23 one year later. Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results also showed that at 30 days post vaccination with either V114 or PCV13 (day 30), immune responses were comparable for both groups across the 13 serotypes shared by the conjugate vaccines and higher in the V114 group for serotypes 22F and 33F, the two serotypes not included in PCV13. In PNEU-DAY (V114-017), a Phase 3 study in immunocompetent adults 18 to 49 years of age with underlying medical conditions associated with increased risk for pneumococcal disease, V114 generated immune responses generally comparable to PCV13 for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. V114 was generally well tolerated in both studies, with a safety profile consistent with that observed for V114 in previously reported studies.

“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “These data provide important information about the potential for V114 followed by PNEUMOVAX 23, a polysaccharide vaccine included in more than 90 percent of age-based adult pneumococcal immunization programs globally, to help protect healthy adults and adults who are at increased risk for pneumococcal disease.”

Findings from the V114 Phase 3 clinical program in adults, including PNEU-PATH and PNEU-DAY, will be presented at a future scientific congress. Plans for global regulatory licensure applications, beginning with the U.S. Food and Drug Administration before the end of the year, remain on track.

Tags : #LatestPharmaNewsOct20 #LatestMerckNewsOct20 #TreatmentforPneumococcalDisease #pneumococcalvaccines

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Stuck in Slow Motion: How Bureaucracy is Choking India’s Pharma DreamFebruary 27, 2025
A New Spine, A New Life: Inside Kerala’s First 3D-Printed Titanium Cage SurgeryFebruary 27, 2025
India’s Newborns Are Dying from Sepsis And No One Is Talking About ItFebruary 27, 2025
Did the Government Force Covid Vaccines Without Responsibility? The Supreme Court Thinks SoFebruary 26, 2025
The Inequality of Survival: Why Some Women Die While Others LiveFebruary 26, 2025
The Corporate Invasion of Indian Hospitals: What It Means for YouFebruary 26, 2025
5 Simple Daily Habits to Keep Your Joints Healthy and Pain-FreeFebruary 25, 2025
Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in IndiaFebruary 25, 2025
With only 70 months left to end AIDS why is the urgency missing?February 25, 2025
Drenched in Oil: Is India Cooking Its Way to an Obesity Epidemic?February 25, 2025
Transforming Education: How Online Learning Platforms are Reshaping Study Material for Board and Competitive ExamsFebruary 24, 2025
February 24, 2025
The Dark Side of India’s Pharma Boom: How Banned Drugs Found a New Market in West AfricaFebruary 24, 2025
The Great Indian Medical Education Paradox: More Seats, Fewer Students, Collapsing SystemFebruary 24, 2025
From Science Fiction to Reality: AI Now Detects Blindness Before It StartsFebruary 24, 2025
Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025